Context. POEMS syndrome is a rare multisystem disorder characterised by polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder and skin changes among other features. Objective. To describe the prevalence and course of the endocrine dysfunction in the context of POEMS. Design. Cohort study with systematic review of the endocrinopathy in POEMS. Setting. 75 patients with POEMS were evaluated by the multidisciplinary team at our tertiary specialist centre. Patients. Endocrine data was available for 59 patients who attended the clinic from 06/1999 to 05/2018. Interventions. All patients had regular endocrine screening including testing for diabetes, pituitary and thyroid dysfunction and assessment of bone metabolism. Main Outcome Measure. Prevalence and survival time to develop endocrinopathy in POEMS.
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SPECIAL REQUESTS:
Enter specific comments or requests to the editors here.
We thank the editor and reviewers for their constructive comments, which have undoubtedly contributed to the improvement of the manuscript. Below we answer the queries received from the reviewers, and describe in detail the changes introduced.
Reviewer Comments:
Reviewer 1: Major Comments 1. The study was retrospective and from 2013 on prospective. The study was performed in a quaternary referral clinic. Therefore the study was susceptible to bias in data selection, analysis and conclusions.
We thank the referee for his/her comment. Due to the extreme rarity of POEMS syndrome, our quaternary referral patient dataset is likely to be the only one in the UK with a significant number of patients that allows a study of this nature. Also, our centre is unique as we have a multidisciplinary approach including endocrine specialist support. Nevertheless, we agree with the referee that our manuscript has inherent limitations due to its observational nature. Thus, we have emphasised this in the limitation section (page 14, lines 301-303: "part of the data was collected retrospectively, therefore it is susceptible to a selection bias. Due to the observation nature of the study, causal relationships cannot be stablished").
2. It is not mentioned that appropriate informed consent was obtained for the prospective part of the study.
We apologise for the lack of clarity and have added the following information into the material and methods section: "All the cohort have signed informed consent for POEMS data collection" (page 6, lines 94-95).
3. Endocrine data were only available from 59 out of 75 patients. No standardized protocol was used to study the incidence and prevalence of the endocrinopathies. Nevertheless, the authors recommended that patients should be systematically assessed for endocrinopathy at each visit.
The referee raises an interesting point. We do have a systematic and standardised protocol at each visit for the endocrine assessment of patients with POEMS syndrome, which includes an order set of blood test and endocrine assessment by an SpR or above. We have clarified this point in the methods section (page 6, line 96-97). In our experience, endocrinopathy can easily be misdiagnosed without a proper screening due to other symptoms (i.e. polyneuropathy) masking the endocrine disease. Of note, our results are in agreement with other studies regarding the high prevalence of endocrine abnormalities in context of POEMS; therefore, it seems reasonable to assess these patients systematically. Nevertheless, we have made a minor change in our conclusion (page 14, line 313).
4. The included patients are phenotypically not well described. No information is presented about prevalence of polyneuropathy, organomegaly, monoclonal gammopathy and skin changes in the study population.
We agree with the referee's comment that this is an important point. All patients had monoclonal gammopathy at diagnosis and all patients except one had polyneuropathy. The one without neuropathy had Castleman variant POEMS. Thirty-five patients (59.3%) had organomegaly and 41 (69.5%) skin changes. We have added this information in the manuscript (page 8, line 144-146). Nevertheless, the complete phenotype of the patient cohort, excluding the endocrine description, is the subject of a publication of the natural history of POEMS syndrome, to be published by or group shortly.
No information is reported about presenting symptoms of POEMS. How often was this an endocrinopathy/gyneacomastia?
This is a very interesting comment. Unfortunately, since endocrinopathy is minor criteria and since thyroid abnormalities are not sufficient to meet the minor criteria, we do not have reliable information about how many patients had endocrinopathy as a presenting symptom or gynecomastia. Even so, we know that 63% of patients had clinical evidence of an endocrinopathy at the point of POEMS diagnosis, but we cannot establish the order of appearance. This data is already in the manuscript (page 8, lines 146-147).
6. The prognosis of POEMS syndrome is dependent on the extent of the underlying plasma cell disorder and its response to treatment. However, the authors did not present any information about underlying plasma disorder, treatment regimens (how many participants were treated by melphalan/corticosteroids/radiotherapy) and responses to treatment.
We acknowledge that this is very important information, however this is not the scope of our manuscript, which aims to focus about the endocrine abnormalities. As we mentioned above, the complete phenotype including treatment and prognosis of the patient cohort is due to be published by our group.
7. Only nine of the thirty-three patients with hyperprolactinaemia underwent a pituitary or head MRI. The authors suggested that an indication to perform a MRI was only present if the hyperprolactinaemia was symptomatic or if prolactin was raised more than 3 times above the upper limit of reference. This is an arbitrary decision rule which is not well supported by arguments.
The referee raises an interesting point and we agree that this is an arbitrary criterion. In our study, the request of an MRI was dependent on the judgement of the clinician. According to endocrine guidelines, MRI should be performed after detail clinical review, after excluding secondary causes of hyperprolactinaemia (i.e drugs) and in case of persistent hyperprolactinaemia; however, the significance and cause of hyperprolactinaemia is unknown in POEMS syndrome. Since there is not consensus for an existent cut-off for prolactin levels to request an MRI, we have deleted this cut-off criteria from our manuscript (page 12, line 252).
8. Page 11, lines 239-241; Since there were no differences between primary and central hypogonadism, the authors suggested that hyperprolactinemia was not the cause of hypogonadism. This is pure speculation. Did they measure levels of gonadotrophines in all participants with hypogonadism? What was their definition of primary and central hypogonadism?
We agree with the referee's comment and we have rephrased "69.2% patients with hyperprolactinaemia had hypogonadism, but there were no differences between primary and central hypogonadism; as hyperprolactinaemia was mild, this suggests the hyperprolactinaemia may not be the cause of the hypogonadism" (page 12, lines 246-248).
LH/FSH was measured in all subjects to differentiate between primary and secondary hypogonadism. We have added the definition of primary and secondary hypogonadism (page 7, lines 116-119).
9. IGF-I was increased while there was no evidence of increased activity of GH. How many of the participants were using corticosteroids with persistent high IGF-I?.
The referee raises an interesting point. Out of five patients with persistent high IGF-1, only one was on hydrocortisone 10/5/5 mg due to adrenal insufficiency. The rest of them were not on treatment with any type of corticosteroids. We have added this information in the manuscript (page 10, line 215-216).
Reviewer 2:
The study conducted by Caimari et al. reports the prevalence and course of endocrinopathy in POEMS. Although several limitations (which are addressed by the authors in the discussion) exist due in part to the retrospective nature of the work, the paper reports original data, with a significant number of patients, in a rare pathological condition. Text and figures are concise and well presented, an upmost need, to make this manuscript one of the reference on the topic of POEMS We thank the reviewer for his/her valuable comment. Results. Thirty-four (63%) patients presented with an endocrinopathy at point of POEMS 43 diagnosis and 54 (92%) had at least one endocrine abnormality at follow-up. The median 44 follow-up was 4.4[1.5, 7.9] years. The most common endocrine abnormality was hypogonadism 45 in 68%, followed by hyperprolactinaemia (56%), hypothyroidism (54%), abnormal glucose 46 metabolism (24%), adrenal insufficiency (17%) and high IGF-1 levels (15%). Spontaneous 47 resolution of endocrine abnormalities at the end of follow-up was observed: 14% in 48 hypogonadism, 42% in hyperprolactinaemia, 34% in hypothyroidism and 38% in high IGF-1 49 levels. 50
Conclusions. Endocrinopathy was found in 63% of patients at diagnosis and in 92% of patients 51 during follow-up in our cohort, therefore patients with POEMS should be systematically 52 assessed for endocrinopathy. The most common deficiencies were hypogonadism and 53 hypothyroidism, however normalisation of the endocrinopathy can occur so on-going treatment 54 should remain under review. Takatsuki syndrome (4). 68 The aetiology of POEMS syndrome is unknown, although an increase in plasma or serum levels 69 of vascular endothelial growth factor (VEGF) is one of the biochemical typical features (4). The 70 diagnosis is often delayed due to the rarity of the syndrome and patients are frequently 71 misdiagnosed with other neurological disorders, most commonly with chronic inflammatory 72 demyelinating polyradiculoneuropathy (5). 73 POEMS syndrome involves multiple organs, and therefore a multidisciplinary approach is 74 usually necessary to treat this group of patients, including a thorough endocrine assessment. 75 Multiple endocrinopathies have been described in POEMS, however the pathogenesis 76 underlying the endocrine abnormalities in POEMS syndrome is unknown. The endocrine 77 dysfunction reported so far is diverse and includes both primary and secondary insufficiencies, 78 such as hypothyroidism, adrenal insufficiency, hypoparathyroidism and hypogonadism (6) as 79 well as excess of hormones with hyperprolactinaemia and hyperparathyroidism (7,8). Pituitary 80 tumours have been described (9), but this could be an incidental finding as the prevalence of 81 these tumours is approximately 20% in the general population (10). 82 There is a significant risk of morbidity from unrecognised endocrinopathy in these patients, 83 especially if there is a lack of a multidisciplinary approach. Little is known about the course and 84 severity of the endocrine dysfunction in POEMS. Here we describe the endocrinopathy at 85 diagnosis and during follow-up in the largest reported European cohort of patients with POEMS 86 syndrome seen at a single specialist centre. 87
MATERIAL AND METHODS 88
Seventy-five patients were identified fulfilling the internationally accepted POEMS diagnostic 89 criteria (see Table 1 at diagnosis, without endocrine follow-up, or followed in another hospital were excluded from 98 this study. Other non-endocrine features and treatment of this cohort of POEMS syndrome 99 patients has been described elsewhere (Keddie et al, manuscript in progress). 100
Definition of variables 101
POEMS syndrome was diagnosed when patient fulfilled the diagnostic criteria (5) ( Table 1) . 102 The date of diagnosis was defined as the date of confirmation of POEMS syndrome. Last 103 follow-up was defined as the last hospital appointment in our institution. 104 We defined endocrine abnormality at diagnosis if the patient presented before or at the moment 105 of POEMS syndrome diagnosis with one or more of the following comorbidities: diabetes 106 mellitus (DM), thyroid disease, hypogonadism, adrenal insufficiency, hyperprolactinaemia, 107 hypo/hyperparathyroidism. We defined endocrinopathy at follow-up if the patient newly 108 presented with any of those abnormalities during follow-up, in addition to abnormal IGF-1 109
levels. 110
New primary hypothyroidism was defined as two separate thyroid stimulating hormone (TSH) 111 levels above the reference range (0.27-4.20 mIU/L). DM and pre-diabetes were diagnosed 112 according to the ADA criteria (11). Hyperprolactinaemia was defined when at least two 113 prolactin levels were above the reference range (324 pmol/L for men and 496 pmol/L for 114 women). Hypogonadism in men was defined when testosterone level at 9 am was below the 115 reference range on at least two occasions (7.6 mmol/L) with elevated LH/FSH in primary 116 hypogonadism and low or normal LH/FSH in secondary hypogonadism. Hypogonadism in 117 women was defined when amenorrhoea was present with low oestrogen, and abnormally low 118 LH/FSH levels in secondary hypogonadism or high LH/FSH levels in primary hypogonadism. 119 Women with amenorrhoea, high LH/FSH levels and above 45 years old were considered to be 120 in the menopause and were thus not considered as having pathological hypogonadism. Adrenal 121 insufficiency was defined as clinical symptoms of hypoadrenalism and basal cortisol below 100 122 nmol/L in the absence of exogenous corticosteroid administration or abnormal short synacthen 123 test. High IGF-1 levels were considered when IGF-1 was elevated above the age adjusted 124 reference range at least on two occasions. 125 
Statistical analysis 126
The Shapiro-Wilks test was used to assess normal distribution for continuous variables. 127
Normally distributed variables were expressed as mean and standard deviation (SD) and were 
RESULTS
136
Baseline characteristics 137
Fifty-nine patients had endocrine follow-up. All patients fulfilled the minimum criteria for 138 POEMS diagnosis ( We have reviewed the course of endocrine dysfunction in a large group of patients with POEMS 220 syndrome. To our knowledge, this is the largest series that systematically reviews the 221 endocrinopathy in this rare condition. It uses endocrine data collected initially retrospectively 222 and later prospectively during follow-up. Our cohort is characterized by diverse endocrinopathy, 223 mostly with more than one endocrine diagnosis, and combining primary and secondary 224 insufficiencies as well as excess of hormonal secretion. 225 In the literature, endocrine dysfunction has been reported in 58-80% of patients (2,7). This is 226 similar to our study, although we report a significant increase in the diagnosis during follow-up 227 (63% at presentation vs 91.5% at follow-up), suggesting that the endocrine screening during 228 follow-up is essential in these patients. 229 Hypogonadism 230
The most frequent endocrine abnormality was hypogonadism (68.4%), but hyperprolactinaemia 231 (55.9%) and hypothyroidism (54.2%) were also common in our cohort, as previously reported 232 (4,7,12). Although, most patients did not have clear causes for the development of 233 hypogonadism, some alternative or additional factors could play roles in development. Firstly, 234 these patients were frequently ill at presentation, with a possible underlying diagnosis of 235 hypothalamic hypogonadism, described in context of severe illness (13,14). Secondly, some of 236 the patients developed primary hypogonadism in the context of melphalan treatment (an 237 alkylating agent known to cause gonadal toxicity)(15), and therefore hypogonadism may not be 238 directly related to POEMS. The combination of these three precipitating factors probably 239 explains why hypogonadism is the most common endocrinopathy in POEMS. 240 
Hyperprolactinaemia 241
Hyperprolactinaemia was the second most common endocrinopathy in our cohort (55.9%), and 242 only a few patients had treatment with drugs that could induce hyperprolactinaemia. In our 243 cohort the frequency of hyperprolactinaemia is higher than previously reported and we 244 hypothesise that this is the direct result of a systematic screening of these patients (7). 245 69.2% patients with hyperprolactinaemia had hypogonadism, but there were no differences 246 between primary and central hypogonadism; as hyperprolactinaemia was mild, this suggests the 247 hyperprolactinaemia may not be the cause of the hypogonadism. We hypothesise that empty 248 sella could also be an expression of endocrine abnormality in POEMS, although an incidental 249
finding cannot be excluded as there are no other cases reported so far. Given only the mild 250 increase in prolactin in most of our patients we suggest that a pituitary MRI should only be 251 requested if the hyperprolactinaemia is persistent or symptomatic. 252 
Hypothyroidism 253
Hypothyroidism was the third endocrine disease in frequency in our cohort (54.2%). Most of 254 our patients (except one with panhypopituitarism), presented with primary hypothyroidism, and 255 half of them had subclinical hypothyroidism. Mild elevation of TSH has been reported in other 256 series (4,7,16). Although hypothyroidism is not considered as part of the POEMS criteria 257 diagnosis, the prevalence of thyroid disease in POEMS is by far much higher in POEMS 258 patients than in general population (17) . 259 
Glycaemic control 260
Patients with type 2 DM accounted for 13.6% in our cohort, however abnormal glucose 261 metabolism reached 23.8% when pre-diabetes was also considered. The prevalence does not 262 differ when compared with general population, although the prevalence of type 2 DM varies by 263 region, age and ethnicity, amongst other factors (18). As type 2 DM has a high prevalence in the 264 population, caution should be taken when considering it as part of the POEMS syndrome, 265 especially if no other endocrine organs are affected and this is the reason why DM is not 266 included in the POEMS diagnostic criteria. Treatment of abnormal glucose metabolism should 267 be in line with usual recommendations. 268 
Adrenal insufficiency 269
Adrenal insufficiency was significant in our cohort (17%). In this group, those who had long 270 term steroid treatment had cortisol deficiency secondary to treatment for POEMS syndrome. 271 However, five of 59 patients (8.5%) had primary adrenal insufficiency. Different from the 272 natural course of other endocrinopathies, adrenal insufficiency was permanent in every patient 273 in our cohort. 274 
IGF-1 levels 275
We report for the first time that patients with POEMS syndrome present with elevated IGF-1 276 levels. In those with persistent high IGF-1, the OGTT, a measure of GH suppressibility, 277 revealed a normal GH-IGF-1 axis. Of note, the increase of IGF-1 was mild in all patients. The 278 significance of this finding is unclear and difficult to explain, especially taking into account that 279 IGF-1 levels are usually low in the context of severe illness (19) and that IGF-1 concentrations 280 are reduced in patients with multiple myeloma (20). Although our patients have hepatomegaly, 281 we have not found any evidence that hepatomegaly is associated with increased IGF-1 282 production. 283 Interestingly, the prevalence of endocrine abnormalities increased during follow-up. The median 284 time to develop any abnormality ranged from 2.6 to 4.3 years after POEMS presentation. This 285 could indicate that the endocrine organ damage continues after controlling the disease. This data 286 was unexpected as it is well described that other features of POEMS syndrome, such as 287 polyneuropathy, improve after treatment (21). On the other hand, we found that endocrine 288 dysfunction can be reversible in POEMS syndrome: 42.4 % patients with hyperprolactinaemia, 289 34.4% of patients with hypothyroidism and 37.5% in high IGF-1 levels demonstrated a transient 290 abnormality. Of note, our patients were characterized by presenting multiple but mild 291
endocrinopathies. 292
Patients received endocrine treatment according to current medical guidelines and generally 293 wellbeing improved in these patients (author's observation). We observed that patients with 294 hypogonadism treated with testosterone had a high risk of polycythaemia. Polycythaemia itself 295 is a feature commonly found in active/unremitted POEMS (2). Therefore, this cohort has a 296 predisposition to develop polycythaemia, also a well-known side effect of testosterone 297 treatment. In our experience, patients who received testosterone injections had higher chance of 298 polycythaemia compared to those treated with gel, and the level of polycythaemia occasionally 299 required cessation of testosterone treatment. 300 This study has some limitations. Firstly, part of the data was collected retrospectively, therefore 301 it is susceptible to a selection bias. Due to the observation nature of the study, causal 302
relationships cannot be stablished. Secondly, due to its observational nature several questions 303 cannot be addressed. These include the cause of the endocrine dysfunction in POEMS 304 syndrome, how and why the endocrine disease can be reversible and why the patients present 305 either hormonal insufficiency or hypersecretion, such as high IGF-1 levels. We will address 306 these questions with studies of a different design. Finally, due to the high incidence in the 307 general population of some of the endocrine diseases such as hypothyroidism or Type 2 DM, 308 the incidental co-association of these abnormalities cannot be excluded, but is recognised. We 309 believe that this study has highlighted several issues, which contribute to the knowledge of this 310 rare but challenging clinical situation. 311
In conclusion, endocrinopathy in POEMS was found in 63% of patients at diagnosis and in 312 91.5% of patients during follow-up in our cohort. We therefore suggest the following 313 recommendations for patients with POEMS syndrome in addition to the multidisciplinary 314 haematological and neurological care. 
